Qingdao Eye Hospital of Shandong First Medical University, Qingdao, China; State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University Qingdao, China.
State Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory of Ophthalmology, Eye Institute of Shandong First Medical University Qingdao, China.
Biomed Pharmacother. 2022 Feb;146:112487. doi: 10.1016/j.biopha.2021.112487. Epub 2021 Dec 6.
Age-related meibomian gland dysfunction (MGD) is the main cause of evaporative dry eye disease in an aging population. Decreased meibocyte cell renewal and lipid synthesis are associated with age-related MGD. Here, we found an obvious decline of Ki67, ΔNp63, and Na/K ATPase expression in aged meibomian glands. Potential Na/K ATPase agonist periplocin, a naturally occurring compound extracted from the traditional herbal medicine cortex periplocae, could promote the proliferation and stem cell activity of meibocyte cells in vitro. Moreover, we observed that periplocin treatment effectively increased the expression of Na+ /K+ ATPase, accompanied with the enhanced expression of Ki67 and ΔNp63 in aged meibomian glands, indicating that periplocin may accelerate meibocyte cell renewal in aged mice. LipidTox staining showed increased lipid accumulation after periplocin treatment in cultured meibomian gland cells and aged meibomian glands. Furthermore, we demonstrated that the SRC pathway was inhibited in aged meibomian glands; however, it was activated by periplocin. Accordingly, the inhibition of the SRC signaling pathway by saracatinib blocked periplocin-induced proliferation and lipid accumulation in meibomian gland cells. In sum, we suggest periplocin-ameliorated meibocyte cell renewal and lipid synthesis in aged meibomian glands via the SRC pathway, which could be a promising candidate for age-related MGD.
年龄相关性睑板腺功能障碍(MGD)是老龄化人群蒸发性干眼症的主要原因。细胞更新和脂质合成减少与年龄相关性 MGD 有关。在这里,我们发现衰老的睑板腺中 Ki67、ΔNp63 和 Na/K ATPase 的表达明显下降。潜在的 Na/K ATPase 激动剂杠柳毒苷是一种从传统草药杠柳皮中提取的天然化合物,可促进体外睑板腺细胞的增殖和干细胞活性。此外,我们观察到杠柳毒苷治疗可有效增加 Na+/K+ATPase 的表达,同时增强衰老的睑板腺中 Ki67 和 ΔNp63 的表达,表明杠柳毒苷可能加速老年小鼠的睑板腺细胞更新。LipidTox 染色显示杠柳毒苷处理后培养的睑板腺细胞和衰老的睑板腺中脂质积累增加。此外,我们证明衰老的睑板腺中 SRC 途径受到抑制,但被杠柳毒苷激活。因此,SRC 信号通路抑制剂 saracatinib 阻断了杠柳毒苷诱导的睑板腺细胞增殖和脂质积累。总之,我们认为杠柳毒苷通过 SRC 通路改善了衰老的睑板腺细胞的更新和脂质合成,这可能是治疗年龄相关性 MGD 的有前途的候选药物。